Remimazolam versus Etomidate for Induction of General Anaesthesia in Elderly Patients: A Randomized Controlled Non-inferiority Trial
In a randomized non-inferiority trial involving 180 elderly patients, remimazolam demonstrated comparable hemodynamic stability and induction speed to etomidate while significantly reducing etomidate-associated myoclonus and post-intubation hypertension, though it necessitated careful monitoring due to a greater pre-intubation drop in mean arterial pressure.
Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). This is an AI-generated explanation of the paper below. It is not written or endorsed by the authors. For technical accuracy, refer to the original paper. Read full disclaimer
Every year, millions of older adults undergo surgery that requires them to be completely asleep. For these patients, the moment the anesthesia begins is a critical window. As people age, their bodies lose some of the flexibility needed to handle sudden stress, and their hearts and blood vessels become less able to adjust quickly. When a patient goes under, their blood pressure can swing wildly—dropping too low and starving organs of oxygen, or spiking too high and straining the heart. Anesthesiologists have long relied on a drug called etomidate to start this process because it is known for keeping blood pressure steady. However, this drug has a rough side effect: it often causes sudden, involuntary muscle jerks that can be uncomfortable and difficult to manage. A newer drug, remimazolam, has emerged as a potential alternative, offering a very fast way to put patients to sleep, but doctors needed to know if it could match the stability of the older drug without causing other problems in fragile, elderly bodies.
To answer this, researchers at Tsinghua University in China conducted a carefully controlled experiment involving 180 elderly patients scheduled for non-cardiac surgery. They divided the patients into two groups: one received the standard etomidate, and the other received the new remimazolam. Both groups received the same additional medications to ensure they were fully unconscious and relaxed before the breathing tube was inserted. The team monitored the patients with extreme precision, tracking their blood pressure and using a specialized monitor that measures brain activity to determine exactly when they lost consciousness. The goal was to see if the new drug could keep blood pressure changes within a safe range and induce sleep just as quickly as the established one, without causing the muscle jerks associated with etomidate.
The results showed that the new drug, remimazolam, performed just as well as etomidate in the two most important areas. When the researchers measured how much the patients' blood pressure changed from their normal baseline during the induction, the difference between the two groups was small enough to be considered clinically equivalent. Similarly, the time it took for the patients to reach a state of deep unconsciousness was nearly identical, with the new drug taking only a few seconds longer on average—a difference so small it did not matter in a real-world operating room. In fact, the new drug proved to be superior in several specific ways. It completely eliminated the involuntary muscle jerks that occurred in nearly one-fifth of the patients receiving etomidate. It also prevented the sharp spikes in blood pressure and heart rate that often happen when the breathing tube is inserted, a reaction that was much more common in the etomidate group.
However, the study also revealed a distinct trade-off. While the new drug was gentler on the heart during the insertion of the breathing tube, it caused a slightly deeper drop in blood pressure before that moment compared to the older drug. About 17 percent of the patients on remimazolam experienced a significant dip in blood pressure, compared to 10 percent on etomidate, though the number of patients who needed medication to fix this low pressure was similar in both groups. The researchers concluded that remimazolam is a viable and effective alternative for elderly patients, offering a smoother experience regarding muscle control and the stress of intubation. The key takeaway is that while it provides a gentler transition into the surgery, it requires the medical team to watch blood pressure closely in the moments before the breathing tube is placed to ensure it does not fall too low. This study does not claim the new drug is perfect for every situation, but it confirms that with careful monitoring, it offers a safer profile for the specific challenges of aging bodies.
Drowning in papers in your field?
Get daily digests of the most novel papers matching your research keywords — with technical summaries, in your language.